Key result
Septal reduction therapy in obstructive HCM shows long-term composite event rates similar to overall cohorts.
Why the study?
Current methods to predict adverse events in HCM rely on retrospective studies from select tertiary centers. This study sought to report long-term outcomes of patients undergoing septal reduction therapies in the prospective NHLBI HCMR registry.
What are the long-term clinical outcomes of hypertrophic cardiomyopathy patients who undergo septal reduction therapies in the NHLBI HCMR registry?
Cohort (n=2,698)
Blinded clinical events committee
Yes
What are the long-term clinical outcomes of hypertrophic cardiomyopathy patients who undergo septal reduction therapies in the NHLBI HCMR registry?
In the prospective HCMR registry, 15.7% of HCM patients underwent septal reduction therapy and experienced low long-term primary adverse event rates (4.3% over 6.9 years) comparable to the overall HCM cohort despite having a more advanced baseline disease phenotype.
Answers are grounded in this paper and cite their sources.
Supports safety of septal reduction in advanced obstructive HCM; extends registry data but leaves open randomized comparisons.
Background[MD1] Current methods to predict risk of adverse events in hypertrophic cardiomyopathy (HCM) are based on retrospective studies from select tertiary centers. The HCM Registry (HCMR) is a prospective registry, funded by the NHLBI, USA to aid in development of clinical and imaging markers that could improve event prediction. Septal reduction therapies (SRT) are highly effective in improving symptoms and quality of life in symptomatic patients with obstructive HCM. We report long-term outcomes of patients in the HCMR registry who underwent SRT during follow-up. Methods Patients enrolled from 44 sites in North America and Europe between 2014-17, received a questionnaire, blood-based biomarker and genetic analysis, and a contrast-enhanced cardiac magnetic resonance imaging (CMR). The composite primary endpoint included: 1. HCM-related cardiovascular deaths including sudden cardiac (SCD), heart failure (HF), stroke, and procedural deaths; 2. Non-fatal ventricular tachyarrhythmias (VT, >200 beats/minute) that required intervention (appropriate internal cardioverter defibrillator [ICD] therapy or external cardioversion/defibrillation); 3. Left ventricular (LV) assist device insertion or heart transplantation. Secondary events included non-cardiac death, HF hospitalization, clinically relevant atrial fibrillation (AF) and non-fatal stroke. All events were adjudicated by a blinded clinical events committee. Results Of the 2698 patients included in the final analysis, 423 (15.7%) underwent SRT (340 (80.4% myectomy, 68 (16.1% alcohol ablation and 15 (3.5%) both) at a mean of 2.6±2.2 years from initial enrollment. Baseline characteristics are shown in Table. Patients undergoing SRT were more likely to be women, with a higher symptom burden and history of HF, more frequently have basal septal hypertrophy, greater degree of mitral regurgitation, higher LV mass and N-terminal brain natriuretic peptide. At a mean of 6.9±2.1 years, out of 117 (4.3%) first primary composite events, 18 (4.3%) occurred in the SRT group (12 [2.8%] were SCD/VT). Of 590 (21.9%) secondary events (59 [2.6%] HF hospitalizations and 245 [10.8%] AF), 194 (45.8%) occurred in the SRT group (HF hospitalization occurred in 23 [5.4%] and AF in 154 [36.4%] patients). In the SRT group, 55.6% of primary events occurred preoperatively, while 11.1% occurred within 30-days postoperatively. Similarly, 4.2% of secondary events occurred preoperatively, while 37.2% occurred within 30-days postoperatively. Event-free curves for the primary composite events and primary SCD/VT events of the SRT patients are shown in Figure 1A and Figure 1B. Conclusions In HCMR registry, 1 in 6 patients, with a higher baseline symptom burden and evidence of more advanced disease phenotype, underwent SRT during follow-up. The long-term primary event rates in the SRT group were low and similar to the overall study population.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2026) conducted a cohort in Hypertrophic cardiomyopathy (HCM) (n=2,698). Septal reduction therapy (myectomy and/or alcohol ablation) vs. Overall study population / patients not undergoing septal reduction therapy was evaluated on Composite of HCM-related cardiovascular deaths (sudden cardiac death, heart failure, stroke, procedural deaths), non-fatal ventricular tachyarrhythmias (>200 bpm) requiring intervention, and LV assist device insertion or heart transplantation. Septal reduction therapy in obstructive HCM patients had a 4.3% long-term primary composite event rate over 6.9 years, similar to the 4.3% rate in the overall HCMR cohort.
Synapse has enriched 10 related papers. Consider them for comparative context: